MUMBAI, India, Aug. 17 -- Intellectual Property India has published a patent application (202511010201 A) filed by Biodeal Pharmaceuticals Limited on February 07, 2025, for A Method For Preparing A Stable, Low-Dose Bilastine Nasal Spray With Enhanced Efficacy And Reduced Side Effects.
Inventor includes Anurag Kumar.
The application for the patent was published on August 14, 2026, under issue no. 33/2026.
Abstract: Low-Dose Intranasal Pharmaceutical Composition Comprising Bilastine ABSTRACT The present invention relates to a low-dose intranasal pharmaceutical composition comprising bilastine and pharmaceutically acceptable excipients, formulated as a stable aqueous nasal spray. The composition is useful for the management of allergic disorders, including allergic rhinitis, by intranasal administration to provide localized therapeutic effect with reduced systemic exposure. The invention further provides a process for preparing the intranasal bilastine composition and a method for managing allergic conditions, wherein the composition exhibits suitable stability, safety, and pharmaceutical acceptability.
Disclaimer: Curated by HT Syndication.
